Amarantus BioSciences, Inc. Engages BD Biosciences for Development of Alzheimer's Diagnostic
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SUNNYVALE, Calif.--(BUSINESS WIRE)--Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it has signed a laboratory services agreement with BD Biosciences, a segment of BD (Becton, Dickinson and Company) , a leading global medical technology company, under which BD’s BD Biosciences Custom Technology Team will perform sample analysis on Amarantus’ LymPro Test® for Alzheimer’s disease. Financial terms were not disclosed.
Help employers find you! Check out all the jobs and post your resume.
SUNNYVALE, Calif.--(BUSINESS WIRE)--Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it has signed a laboratory services agreement with BD Biosciences, a segment of BD (Becton, Dickinson and Company) , a leading global medical technology company, under which BD’s BD Biosciences Custom Technology Team will perform sample analysis on Amarantus’ LymPro Test® for Alzheimer’s disease. Financial terms were not disclosed.
Help employers find you! Check out all the jobs and post your resume.